304 related articles for article (PubMed ID: 32627025)
1. Improving the odds of success in antitumoral drug development using scoring approaches towards heterocyclic scaffolds.
Ion GND; Olaru OT; Nitulescu G; Olaru II; Tsatsakis A; Burykina TI; Spandidos DA; Nitulescu GM
Oncol Rep; 2020 Aug; 44(2):589-598. PubMed ID: 32627025
[TBL] [Abstract][Full Text] [Related]
2. An overview of quinoline as a privileged scaffold in cancer drug discovery.
Musiol R
Expert Opin Drug Discov; 2017 Jun; 12(6):583-597. PubMed ID: 28399679
[TBL] [Abstract][Full Text] [Related]
3. Steering the antitumor drug discovery campaign towards structurally diverse indolines.
Thakur A; Singh A; Kaur N; Ojha R; Nepali K
Bioorg Chem; 2020 Jan; 94():103436. PubMed ID: 31761410
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.
Holbeck SL; Collins JM; Doroshow JH
Mol Cancer Ther; 2010 May; 9(5):1451-60. PubMed ID: 20442306
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative Activity Predictor: A New Reliable In Silico Tool for Drug Response Prediction against NCI60 Panel.
Martorana A; La Monica G; Bono A; Mannino S; Buscemi S; Palumbo Piccionello A; Gentile C; Lauria A; Peri D
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430850
[TBL] [Abstract][Full Text] [Related]
6. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Kong D; Yamori T
Bioorg Med Chem; 2012 Mar; 20(6):1947-51. PubMed ID: 22336246
[TBL] [Abstract][Full Text] [Related]
7. Chromones: Privileged scaffold in anticancer drug discovery.
Patil VM; Masand N; Verma S; Masand V
Chem Biol Drug Des; 2021 Nov; 98(5):943-953. PubMed ID: 34519163
[TBL] [Abstract][Full Text] [Related]
8. A Medicinal Chemist's Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents.
Nehra B; Mathew B; Chawla PA
Curr Top Med Chem; 2022; 22(6):493-528. PubMed ID: 35021975
[TBL] [Abstract][Full Text] [Related]
9. Tailored Quinolines Demonstrate Flexibility to Exert Antitumor Effects through Varied Mechanisms-A Medicinal Perspective.
Sharma S; Singh A; Sharma S; Sharma R; Singh J; Kinarivala N; Nepali K; Liou JP
Anticancer Agents Med Chem; 2021; 21(3):288-315. PubMed ID: 32900354
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives.
El-Gamal MI; Khan MA; Tarazi H; Abdel-Maksoud MS; Gamal El-Din MM; Yoo KH; Oh CH
Eur J Med Chem; 2017 Feb; 127():413-423. PubMed ID: 28088086
[TBL] [Abstract][Full Text] [Related]
11. Anticancer SAR models for MCF-7 and MDA-MB-231 breast cell lines.
Qamar S; Carrasquer CA; Cunningham SL; Cunningham AR
Anticancer Res; 2011 Oct; 31(10):3247-52. PubMed ID: 21965732
[TBL] [Abstract][Full Text] [Related]
12. Quantitative and Qualitative Analysis of the Anti-Proliferative Potential of the Pyrazole Scaffold in the Design of Anticancer Agents.
Nitulescu GM
Molecules; 2022 May; 27(10):. PubMed ID: 35630776
[TBL] [Abstract][Full Text] [Related]
13. Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery.
Khwaza V; Mlala S; Oyedeji OO; Aderibigbe BA
Molecules; 2021 Apr; 26(9):. PubMed ID: 33918996
[TBL] [Abstract][Full Text] [Related]
14. Anticancer platinum(II) complexes bearing N-heterocycle rings.
Facchetti G; Rimoldi I
Bioorg Med Chem Lett; 2019 Jun; 29(11):1257-1263. PubMed ID: 30935797
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics.
Lu Y; Yin W; Alam MS; Kadi AA; Jahng Y; Kwon Y; Rahman AFMM
Anticancer Agents Med Chem; 2020; 20(4):464-475. PubMed ID: 31763968
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities.
Akhtar MJ; Yar MS; Khan AA; Ali Z; Haider MR
Mini Rev Med Chem; 2017; 17(17):1602-1632. PubMed ID: 27804888
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative effect, cell cycle arrest and apoptosis generation of novel synthesized anticancer heterocyclic derivatives based 4H-benzo[h]chromene.
Alblewi FF; Okasha RM; Hritani ZM; Mohamed HM; El-Nassag MAA; Halawa AH; Mora A; Fouda AM; Assiri MA; Al-Dies AM; Afifi TH; El-Agrody AM
Bioorg Chem; 2019 Jun; 87():560-571. PubMed ID: 30928878
[TBL] [Abstract][Full Text] [Related]
18. Chalcogen containing heterocyclic scaffolds: New hybrids with antitumoral activity.
Alcolea V; Plano D; Encío I; Palop JA; Sharma AK; Sanmartín C
Eur J Med Chem; 2016 Nov; 123():407-418. PubMed ID: 27487570
[TBL] [Abstract][Full Text] [Related]
19. Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era.
Yadav S; Narasimhan B; Kaur H
Anticancer Agents Med Chem; 2016; 16(11):1403-1425. PubMed ID: 26526461
[TBL] [Abstract][Full Text] [Related]
20. Overview of recent developments of pyrazole derivatives as an anticancer agent in different cell line.
Bennani FE; Doudach L; Cherrah Y; Ramli Y; Karrouchi K; Ansar M; Faouzi MEA
Bioorg Chem; 2020 Apr; 97():103470. PubMed ID: 32120072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
